TAK-611

DB17644InvestigationalProtein Based Therapies

TAK-611, formerly known as SHP611, is a recombinant human arylsulfatase A. First developed by Takeda, it is being investigated for the treatment of metachromatic leukodystrophy.

Mechanism: Pharmacologically active on Arylsulfatase A
Curator reviewed
Code names: HGT-1110 · SHP-611 · TAK-611

Resolves to

Compound

UNIIKK93B9NF24

Targets

P15289ARSA

What you can answer from here — as of July 11, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

2Clinical trialsPhase, status and sponsor resolved per trial

3+ReferencesStructured and connected to the statements they support

Which drugs share a target with TAK-611, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account